Tuberculosis multidrogorresistente / Multidrug-resistant tuberculosis / Tuberculose multirresistente
Rev. salud bosque
;
10(1): 1-10, 2020. Tab, Ilus, Graf
Article
in Spanish
| LILACS, COLNAL
| ID: biblio-1104438
RESUMEN
La tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos antituberculosos), tiene una relevancia particular de los 10 millones de personas que desarrollan TB anualmente, 458.000 presentan TB-MDR con un pronóstico mucho peor que el de los infectados por cepas sensibles. En el presente artículo se exploran los principales aspectos de la TB-MDR, haciendo énfasis en su tratamiento
ABSTRACT
Tuberculosis (TB) is the worldwide leading infectious cause of death and, the emergence of drug-resistant tuberculosis can only worsen the scenario. Multidrug-Resistant Tuberculosis (TB-MDR) has proven resistant to both isoniazid and rifampin, the main antituberculous drugs. Out of 10 million people developing TB annually, 458 000 exhibit TB-MDR, having worse prognosis than those infected by sensitive strains. Recently, new drug-resistant TB treatment guidelines were issued both by the World Health Organization and health authorities in Colombia. The present paper explores the main aspects of TB-MDR emphasizing s sanitary authorities also, new guidelines were published by Colombian minister of health and social protection. In this paper, the main aspects of TB-MDR are explored, especially those related to its treatment.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Tuberculosis, Multidrug-Resistant
/
Antitubercular Agents
Type of study:
Practice guideline
Country/Region as subject:
South America
/
Colombia
Language:
Spanish
Journal:
Rev. salud bosque
Journal subject:
Medicine
Year:
2020
Type:
Article
Affiliation country:
Colombia
Institution/Affiliation country:
Los Cobos Medical Center, Departamento de Investigaciones/CO
Similar
MEDLINE
...
LILACS
LIS